Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1230Neoplasms 1040Carcinoma, Non-Small-Cell Lung 757Prostatic Neoplasms 697Colorectal Neoplasms 598Lung Neoplasms 578Pancreatic Neoplasms 403Leukemia, Myeloid, Acute 399Neoplasm Metastasis 391Ovarian Neoplasms 373Multiple Myeloma 373Stomach Neoplasms 319Carcinoma, Hepatocellular 304Melanoma 284Brain Neoplasms 281Recurrence 280Squamous Cell Carcinoma of Head and Neck 269Head and Neck Neoplasms 240Endometrial Neoplasms 236Glioblastoma 235Triple Negative Breast Neoplasms 230Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Lymphoma 226Uterine Cervical Neoplasms 225Sarcoma 202Hematologic Neoplasms 201Urinary Bladder Neoplasms 197Esophageal Neoplasms 192Carcinoma, Renal Cell 191Lymphoma, Non-Hodgkin 177

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Unresectable Locally Recurrent Breast Cancer × 1 year × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡